Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
JNJ-28312141
227
CHF
CHF 227.00
In stock
SYN-1154-M0011 mgCHF 227.00
SYN-1154-M0055 mgCHF 461.00
SYN-1154-M01010 mgCHF 724.00

Product Details | |
---|---|
Synonyms | JNJ28312141 |
Product Type | Chemical |
Properties | |
Formula | C26H32N6O2 |
MW | 460.6 |
CAS | 885692-52-4 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO or ethanol. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: CSF1R, FLT3 | Kinase Group: CMGC | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | GUBJNPWVIUFSTR-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
JNJ-28312141 is an orally active tyrosine kinase inhibitor for FMS with an IC(50) of 0.69nM and a cell assay IC(50) of 2.6nM. It is an active CSF1R inhibitor (Colony-stimulating factor-1 receptor) and also a FLT3 inhibitor.
Product References
- JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia: C.L. Manthey, et al.; Mol. Cancer Ther. 8, 3151 (2009)